https://www.thebodypro.com/category/adverse-events-comorbidities-hiv/tag/hepatitis-c

The Latest

doctor patient hands

This Week in HIV Research: Health in Unity

Jan. 21, 2021: Dyad-level interventions in serodiscordant relationships; using social media to improve PrEP uptake; HCV prevalence among MSM; the irrelevance of doxycycline prophylaxis against mycoplasma genitalium.

By Barbara Jungwirth and Myles Helfand
prescription telemedicine

Can a Low-Contact, Minimal Monitoring Approach Become the New Normal for Treating Hepatitis C?

No baseline genotyping. Fewer in-person medical visits and lab tests. No need for refills. Could the future of HCV treatment take place almost entirely remotely?

By Terri Wilder, M.S.W.
Biden Harris

Will the Biden-Harris Administration Breathe Life Back Into Vital HIV and Hepatitis Programs?

We spoke with Amy Killelea at NASTAD, a major national health policy advocacy organization, about the priorities she sees in January 2021 and beyond.

By Terri Wilder, M.S.W.
COVID-19 mask profile

This Week in HIV Research: The Real-World Effects of COVID-19

Oct. 22, 2020: Impact of COVID-19 shutdowns on HIV viral suppression; unsuppressed HIV viral load despite no treatment failure; point-of-care rapid testing vs. lab testing; it's not about "what," it's about "when."

By Barbara Jungwirth and Myles Helfand
prison

Hepatitis C Treatment Barriers Persist Through the Cure Era, Especially in U.S.

For the most vulnerable populations disproportionately impacted by HCV in the U.S.—i.e., incarcerated people and people who inject drugs—treatment remains dangerously elusive, experts say.

By Ginger Skinner
Hep C virus

This Week in HIV Research: Hep C, That Other Epidemic Within an Epidemic

Sept. 3, 2020: A hepatitis C microelimination program for people living with HIV; PrEP concentrations and gender-affirming hormones; a collaborative intervention to improve opioid prescribing practices; TDF and fracture risk.

By Barbara Jungwirth and Myles Helfand
Annette Gaudino and Bryn Gay

With Several Curative Therapies for Hepatitis C on the Market, the Research Pipeline for Prevention Continues

The authors of an influential annual report on hepatitis C research and development talk through what's new and evolving in clinical science.

By Terri Wilder, M.S.W.
mouth to ear

This Week in HIV Research: Why Aren’t We Listening to Ourselves?

Aug. 13, 2020: HCV testing rates among people newly diagnosed with HIV; HCV treatment referrals ammong coinfected people; HIV mortality rates despite free treatment access; mysterious, plummeting CD4 test results.

By Barbara Jungwirth and Myles Helfand
COVID-19 patient care-iStock-1218539192

Can Drugs That Cure Hepatitis C Treat COVID-19? Here’s the State of the Research So Far.

An interview with Andrew Hill, Ph.D., about his research presented at AIDS 2020.

By Terri Wilder, M.S.W.
mental connection

This Week in HIV Research: The Mind Matters

July 23, 2020: Depression and HIV risk mitigation among MSM; a consistent HIV provider is good for CD4 and viral load; spirituality and HIV prevention; HCV treatment access and reinfection risk.

By Barbara Jungwirth and Myles Helfand